Shopping Cart
- Remove All
Your shopping cart is currently empty
MYCi361 (NUCC-0196361) is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $118 | In Stock | |
| 5 mg | $287 | In Stock | |
| 10 mg | $457 | In Stock | |
| 25 mg | $753 | In Stock | |
| 50 mg | $1,060 | In Stock | |
| 100 mg | $1,430 | In Stock |
| Description | MYCi361 (NUCC-0196361) is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM). |
| Targets&IC50 | MYC:3.2 μM(Kd) |
| In vitro | MYCi361 is a small-molecule MYC inhibitors that inhibits the viability of MYC-dependent cancer cells including prostate cancer (MycCaP, LNCaP, and PC3), leukemia (MV4-11), lymphoma (HL-60 and P493-6), and neuroblastoma (SK-N-B2) with low-micromolar IC50 values[1]. |
| In vivo | MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. |
| Animal Research | FVB or NSG male mice of 6-8 weeks of age and 25 g bearing established MycCaP tumors.MYCi361 treatment i.p. initially at 50 mg/kg twice daily for 2 days, then 70 mg/kg/day for 9 days |
| Synonyms | NUCC-0196361 |
| Molecular Weight | 594.86 |
| Formula | C26H16ClF9N2O2 |
| Cas No. | 2289690-31-7 |
| Smiles | Cn1nc(cc1-c1ccc(OCc2ccc(Cl)cc2)c(c1O)-c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (168.1 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.